Dublin, March 28, 2019 (GLOBE NEWSWIRE) -- The "Contraceptives: Opportunity Analysis and Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering.
Contraceptive market sales were estimated to be $6.3bn across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China) in 2017, which is expected to grow to $8.2bn in 2027, at a compound annual growth rate of 2.7%.
"Contraceptives: Opportunity Analysis and Forecasts to 2027", states that the launch of four novel contraceptive drug candidates will drive growth of the female contraceptive market over the forecast period. Launching products include Mithra's combined pill, Estelle, Evofem's non-hormonal gel, Amphora, The Population Council's and Antares' transdermal gel, Nestragel, and The Population Council's and Therapeutics MD's extended-release vaginal ring, Annovera (already approved in the US).
Increased contraceptive choices will raise the chance of finding suitable contraceptives for individual needs, whilst increasing contraceptive market growth in the next ten years.
The majority of contraceptives sales will come from the US, attributable to the new product launches. Japan's sales will fall at a negative CAGR of 1.1% by 2027 as a result of a decreasing female population. China, on the other hand, will become the fourth largest contraceptive market by 2027 as a result of a growing population and growing demand for contraceptives, in spite of the lack of launch of a new contraceptive, indicating a great opportunity for foreign drug developers to enter the Chinese contraceptive market.
Presently, marketed contraceptives can cause damaging side effects and are one of the main reasons why patients may decide to discontinue contraceptive use, leading to unintended pregnancies. Therefore, the launch of the four drugs will fill important unmet needs and shape the contraceptive space.
Contraceptives in late-stage clinical development, Phase IIb and Phase III, contain novel, more natural progesterones or estrogens that are aimed at decreasing androgenic and estrogenic side effects, respectively, associated with current formulations.
An interesting product in Phase III is Evofem's Amphora, which is a non-hormonal vaginal gel designed to maintain an acidic environment, which is inhospitable to sperm as well as certain pathogens. If it proves effective against certain investigated sexually transmitted disease (STD) prevention, its dual benefit will make this contraceptive a desirable method of contraception.
Key Questions Answered
Scope
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Contraceptives: Executive Summary
2.1 Moderate Growth in the Contraceptives Market Is Expected Between 2017 and 2027, Driven by US and China Sales
2.2 Developers Targeting Other Female Health Conditions in Addition to Contraception
2.3 The Contraceptives Market Is Still in Need of Therapeutics with Better Safety Profiles
2.4 Significant Opportunity Remains in Chinese and Japanese Contraceptives Markets
2.5 The Diverse Late-Stage Pipeline Offers Women More Options for Contraception
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Contraception
4.2 Other Indications
5 Current Treatment Options
5.1 Overview
6 Unmet Needs and Opportunity Assessment
6.1 Overview
6.2 Hormonal Contraceptives with Reduced Adverse Reactions
6.3 Non-hormonal Contraceptives
6.4 Better Compliance and Adherence to Contraceptives
6.5 Access to a Wide Range of Contraceptive Methods
6.6 Awareness of Different Contraceptive Methods
7 R&D Strategies
7.1 Overview
7.1.1 Development of Novel Non-hormonal Contraceptives
7.1.2 Utilization of Contraceptives for Other Disease Indications
7.1.3 New Drug Delivery Technologies
7.2 Clinical Trials Design
7.2.1 Pearl Index as an Efficacy Tool
7.2.2 Selection of an Active Comparator
8 Pipeline Assessment
8.1 Overview
8.2 Innovative Early-Stage Approaches
9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.2 Commercial Benchmark of Key Pipeline Drugs
9.3 Competitive Assessment
9.4 Top-Line 10-Year Forecast
9.4.1 US
9.4.2 5EU
9.4.3 Japan
9.4.4 China
10 Appendix
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/research/gs7ntt/global?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Women's Health